Tarsus Pharmaceuticals Profit Margin

Tarsus Pharmaceuticals (TARS) currently reports a profit margin of -9.02% as of March 2026. That compares with -44.91% in the prior-year period — up 79.9% year over year. That is below the Healthcare sector average of 15.29%. Use the charts on this page to explore Tarsus Pharmaceuticals's profit margin history and peer comparisons.

Tarsus Pharmaceuticals's profit margin increased from -44.91% to -9.02% — a 79.9% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Tarsus Pharmaceuticals's profit margin of -9.02% is lower than the Healthcare sector average of 15.29%. That is roughly 159.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Tarsus Pharmaceuticals's current -9.02% should be judged against Healthcare norms (sector average: 15.29%) and against TARS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -9.02%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.29%. From there, open related valuation or income-statement pages for Tarsus Pharmaceuticals, and consider following TARS for alerts when major investors trade the stock.